• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Analysis of adverse events following 2009 influenza A (H1N1) vaccinoprophylaxis in Beijing

tetano

Editor, Senior Moderator
Zhonghua Yu Fang Yi Xue Za Zhi. 2010 Oct;44(10):884-887.
[Analysis of adverse events following 2009 influenza A (H1N1) vaccinoprophylaxis in Beijing.]

[Article in Chinese]

Miao L, Lu L, Wu J, Suo LD, Liu DL, Sun MP, Pang XH, Deng Y, Wang XL.

Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing 100013, China. Email: lmiao168@hotmail.com.
Abstract

OBJECTIVE: To evaluate the safety of 2009 influenza A (H1N1) vaccine based on mass immunization initiative in Beijing.

METHOD: There were 2 113 280 people were vaccinated during September to December 2009. The information of adverse events following immunization (AEFI) was collected through surveillance system, and descriptive methodology was used for data analysis.

RESULTS: A Total of 612 AEFI cases were reported, among which there were 321 vaccine reaction cases following immunization, 203 coincidental illness cases, 82 psychogenic reaction cases, and 6 pending cases. The rates of rare reactions and common reactions associated with vaccination were respectively 5.54/100 000 (117/2 113 280) and 9.65/100 000 (204/2 113 280). The rate of serious rare reaction was 0.19/100 000 (4/2 113 280). The rates of vaccine reactions in urban, suburb and county were 16.87/100 000 (36/213 519), 17.81/100 000 (187/1 049 817) and 11.53/100 000 (98/849 944), respectively. The rates of rare reaction and common reaction in different age groups were between 3.65/100 000 (6/164 604) to 8.99/100 000 (27/300 176), and between 0.61/100 000 (1/164 604) to 22.06/100 000 (85/385 275). The 117 rear vaccine reaction cases were mainly allergic reaction (107 cases), and the 204 common vaccine reaction cases were mainly fever (176 cases). There were 91.90% (295/321) vaccine reactions occurred within 24 hours of administration, and all cases had improved consequence.

CONCLUSION: The mostly symptoms of AEFI cases during the period of 2009 influenza A (H1N1) vaccinoprophylaxis were anaphylaxis and fever. The types of adverse reactions and the level of serious events are consistent with the anticipation. There were no rear or new events occurred.

PMID: 21176517 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21176517
 
Back
Top Bottom